Rating: Cautiously Bullish | Target Price: HKD 5.0–6.5 (base-case fair value range) | Current Price: HKD 4.63 (close on 2026-10-09) | Margin of Safety: ~8% (measured against base-case fair value floor of HKD 5.0) | Time Horizon: 12–18 months
Market cap ~HKD 3.13 billion (677 million shares issued, per 2026-09-30 monthly return) | Exchange: HKEX Chapter 18A | Core Business: Structural Heart Interventional Devices (TAVR/TEER) + Neurointerventional Devices
Financials are denominated in RMB unless otherwise stated; valuation and share prices are in HKD. FX convention: RMB 1 ≈ HKD 1.173 (as of 2026-10-09).
Peijia Medical is a rare HK-listed 18A medical device company that has reached the "eve of profitability inflection": in H1 2026, it achieved its first positive half-year pre-tax profit since listing (+RMB 0.7 million), with EBITDA of +RMB 47.4 million and operating cash flow of +RMB 49.4 million both turning positive simultaneously; its transfemoral TAVR market share has risen into the top domestic tier (~21% on total-procedure basis, ~26.4% on transfemoral-denominator basis), and TaurusTrio (the only transfemoral TAVR approved in China for aortic regurgitation) plus GeminiOne TEER, newly approved in September, form the incremental new-product drivers for 2027. The current price of HKD 4.63 corresponds to a PS(2026E) of ~3.1x, implying the market requires only "zero growth + 13% net margin" for the valuation to be self-consistent — more conservative than the company's actual trajectory; however, most of the direct discount versus pure-play neurointerventional peers is explained by business-mix differences (~49% of revenue comes from TAVR, which is in a price war), and on a blended-business basis the actual discount narrows to ~6–18%, part of which also reflects the structural discount of low 18A liquidity (average daily turnover ~HKD 2.3–3.3 million). Overall judgment: modestly undervalued — base-case fair value HKD 5.0–6.5, probability-weighted center ~HKD 5.5 (implied expected return ~+19%); but full-year breakeven is a near-line event, the valve provincial-alliance centralized procurement tender remains unresolved (a two-way swing factor), and low liquidity means odds realization will be highly volatile — cautiously bullish; participate in tranches, with dynamic reviews tied to verification milestones.
One-line opportunity definition: The profitability inflection has been first-hand verified by the 2026 interim report (pre-tax/EBITDA/operating cash flow all turned positive), with volume ramp of the AR-dedicated valve and TEER dual new categories underway, while the current price implies only conservative pricing; the next 12–18 months are a dual near-line gamble between "2026 full-year breakeven verification" and "valve centralized procurement tender."
Evidence grade: B (all core financial figures traceable to the 2026 interim report and FY2025 annual report originals; but TAVR market share, TEER competitive positioning, and some industry sizing rely on company-disclosed or secondarily cited data, with no independent third-party share data).
Market environment fit: Neutral. Funding conditions in the HK 18A medical sector remain cold, with average daily turnover of ~HKD 2.3–3.3 million, only ~0.01% of market cap, and high institutional entry/exit costs — this is part of the valuation discount and also explains why good news fails to sustainably lift the share price (evidenced by the stock staying at the lower end of its 52-week range of HKD 3.73–7.37 even after the August interim report's triple-positive results and September's GeminiOne approval).
Changes most likely to reprice the stock over the next 6–12 months: ① The positive profit alert window in Jan–Feb 2027 and the annual report in March, formally verifying "full-year breakeven" (H2 FX and fair-value gains/losses are the biggest swing items, dragging ~RMB 25 million combined in H1); ② The opening of the Gansu-led cardiac valve provincial-alliance centralized procurement tender — a mild scenario (proposed winning price ≥ RMB 150,000/unit) removes the overhang, while an aggressive scenario (< RMB 130,000) triggers the bear case; ③ Approval of the third-generation dry valve TaurusNXT (accepted 2025-12; based on GeminiOne's ~11-month review pace, window 2026Q4–2027Q1); ④ GeminiOne hospital listing and initial implantation pace.
Primary share-price drivers: Full-year breakeven verification > TAVR volume growth offsetting price cuts (Trio monthly implants reached 330 in July) > centralized procurement tender outcome (largest two-way swing factor).
Verifiable expectation gaps: The current price back-solves to implied normalized net profit of ~RMB 107 million (25x mature PE × 13% net margin × ~RMB 820 million revenue, zero growth), while the company's 2026H1 revenue grew +20.1% and recurring profit excluding Frontier Technologies was ~+RMB 24 million, already on track; peers Genesis Medtech (归创通桥) and MicroVention-affiliated Neuroscientx (微创脑科学) have achieved ~23% net margins, proving 13% is a conservative floor. However, it must be emphasized: sell-side consensus target prices of HKD 9.81–10.09 (4 Buy/0 Sell) were mostly formed when the stock traded at HKD 5–7.4, without downward revision after the price pullback, and coverage is thin — they cannot be treated as a reliable consensus anchor.
Catalysts for verification and falsification conditions: See "Overall Conclusion and Monitoring" at the end.
Key evidence:
Three hedges must be squarely acknowledged: First, H1 profit improvement partially relied on cost compression — within the -23.5% decline in R&D expenses, external R&D professional service fees plunged from RMB 17.61 million to RMB 1.11 million (contributing ~RMB 16.5 million in one-off savings), while key pipelines remain in progress (TaurusNXT review, HighLife/MonarQ clinical trials); a rebound in R&D spending is only a matter of time. Second, H1 net FX loss of RMB 13.1 million plus fair-value changes in financial assets of -RMB 11.96 million dragged ~RMB 25 million combined; the company explicitly stated it does not use hedging instruments, so this item could recur in H2. Third, income tax expense of RMB 9.69 million (including deferred tax expensing) means breakeven at the attributable level requires pre-tax profit of ~RMB 10 million or more, not near-zero. Against H2-2025 attributable loss of ~RMB 133 million, full-year breakeven requires YoY improvement of ~RMB 140 million, about 2.3x the H1 improvement magnitude — "inflection verified, breakeven near-line" is this report's precise characterization of C1.
Key evidence:
Share data must be presented in dual frames: on total industry volume of 18,636 cases, share is ~20.9%; on a "transfemoral denominator" (18,636 × 79.23% ≈ 14,773 cases), ~26.4% — the latter is the company's own calculation basis, and the transfemoral share assumption (79.23%) has no independent third-party verification; the "domestic No. 1" claim also lacks first-hand corroboration of Venus Medtech's 2025 implant volume (its 2025 revenue of -34.8% supports the direction of competitive improvement, but no quantitative implant figures). On price: starting January 2026, multiple provinces cut TAVR listing prices (the company's three products uniformly adjusted to RMB 159,900/unit in Liaoning; industry listing anchor ~RMB 150,000–160,000); H1 ex-factory ASP was ~RMB 73,200/unit, down only -6.1% YoY — but this blended figure was structurally protected by the rising share of the high-priced Trio (implied ex-factory price declines for AS-category products were larger); as listing prices transmit and Trio mix rises, H2 ASP declines should become visible. Industry-wide, 2025 procedure volume growth slowed to +8.1% (2023 +73%, 2024 +36%); Peijia's +36.5% implant growth is roughly 4x the industry (total-volume basis) — share capture is real, but "industry cake re-acceleration" (price cuts → second wave of penetration) can only be confirmed once full-year 2026 industry data is out.
Key evidence:
China's TEER market saw ~4,334 implants in 2025 (+72.9%), with penetration below 0.1% of the intervention-eligible patient base — rapid track expansion; but Peijia is a latecomer: first mover Dejin has claimed the No. 1 share position, Abbott's academic standing is solid, and TEER procedures are strongly self-paid, requiring dual interventional and ultrasound team training at each center, so ramp-up follows the long cycle of "hospital entry → operator training → volume." Referencing the first mover's post-approval first-year curve, 400–700 GeminiOne cases in 2027, contributing RMB 50–100 million in revenue at the mainstream domestic price band, is a neutral expectation; if hospital entries fall below 80 or implants below 150 within 6 months of approval (versus the benchmark of TaurusTrio's 660 cases in its first 6 months), the second-curve narrative degrades into follower status. First-year TEER academic promotion and training costs are front-loaded, so 2027 will most likely be a net drag on the income statement — the correct expectation is "revenue increment + long-term option," not a near-term profit engine.
Key evidence:
The neurointerventional segment, contributing ~51% of revenue, accounts for all of the group's operating profit (H1 segment profit +RMB 73.2 million vs valve segment -RMB 9.7 million) — it is the cash flow cushion during the TAVR ramp period. But three constraints must be stated: ① The most comparable peer, Neuroscientx, posted only +3.8% revenue and -26.2% net profit in 2025 — industry profit contraction under the centralized procurement renewal cycle has peer-level evidence; Peijia's 33.7% segment margin sits at a high level in a downcycle; ② The first-round coil procurement average price cut of 46.8% has been digested, but the Jiangsu renewal cut a further ~10%, and multiple renewal and new volume-based procurement projects are proceeding; ③ The -15.4% access-category decline (the volume base) is a structural deterioration signal, and within the +45.4% ischemic growth some is contribution from exclusively distributed third-party products, diluting gross margin quality. Each 1 percentage point decline in margin cuts half-year segment profit by ~RMB 2.17 million — a key variable for the quality of the group's "profit turn positive."
Key evidence:
This report's key difference from the initial judgment lies in the correction of the peer anchor: ~49% of Peijia's revenue comes from TAVR, which is in a price war, so it cannot be benchmarked directly at the 4.6–5.0x PS of pure neurointerventional peers. Blending by business (neuro 51% × 5.0x + TAVR 49% × 1.5–2.5x, with the TAVR comparable range using Venus's 1.33x distressed level as the lower bound and Vitruvia's (心通) 2.47x as the upper bound reference) back-solves to fair PS of ~3.3–3.8x, narrowing the discount versus the current 3.11x to 6–18%; further factoring in the low-liquidity discount of ~HKD 2.3–3.3 million daily turnover (high institutional entry/exit costs; 20–30% discounts are routine in 18A rather than evidence of mispricing), the mispricing component narrows further. The current price's implied expectations are indeed conservative (zero growth + 13% net margin vs actual +20% growth), PB sits at a low percentile over the past year, and sell-side targets have not been revised down — but "the stock staying at the 52-week low even after the interim triple-positive results and GeminiOne approval" shows the market is not pricing in the good news, and there is no timetable for expectation-gap closure in a low-liquidity name. This report therefore characterizes it as modestly undervalued rather than deeply undervalued: base-case fair value HKD 5.0–6.5, with upside realization tied to two unresolved events — breakeven verification and a mild centralized procurement outcome.
Table: Core financials for the past three years and latest period (RMB million)
| Metric | FY2023 | FY2024 | FY2025 | 2026H1 (latest period) |
|---|---|---|---|---|
| Revenue | 441.1 | 615.5 | 712.9 | 424.5 |
| Revenue YoY | +75.9% | +39.5% | +15.8% | +20.1% |
| Gross margin | 73.8% | 70.5% | 68.2% | 68.3% |
| Net profit attributable to owners | -392.5 | -226.6 | -203.3 | -7.6 |
| Profit excluding frontier technologies (our estimate*) | — | -197.3 | -106.5 | +24.0 |
| R&D expenditure | — | 203.4 | 254.4 | 88.4 |
| R&D expense ratio | — | 33.0% | 35.7% | 20.8% |
| Selling and distribution expense ratio | — | — | 45.0% | 27.6% |
| EBITDA | — | — | — | +47.4 |
| Operating cash flow | -631.0 | -5.2 | -21.0 | +49.4 |
| Cash + time deposits + restricted cash (period-end) | — | 707.8 | 610.3 | 811.1 |
| Of which: unlisted equity investments (FVTPL) | — | — | 337.3 | 316.0 |
| Interest-bearing borrowings (period-end) | — | 248.1 | 428.6 | 649.1 |
| Gearing ratio (total liabilities/equity) | — | 31.5% | 43.0% | 57.2% |
*Exclusion basis = net profit attributable to owners plus frontier technology segment loss (FY2024: -228.5+31.2=-197.3; FY2025: -203.3+96.8=-106.5; 2026H1: -9.0+33.0=+24.0, in RMB million). The company does not disclose Non-IFRS adjusted profit; this is our estimate of a recurring basis, which still needs to absorb unallocated finance costs and group-level items, for reference only. Balance-sheet stock figures are period-end values (latest period as of 2026-06-30).
Drivers of metric changes (items with YoY change ≥ ±20%, with company explanations):
2026H1 revenue was RMB 424.5 million, +20.1% YoY, within the range of the company's 2026-08-07 operational update (RMB 415–435 million); net loss attributable to owners narrowed 89.1% to RMB 7.59 million, EBITDA +RMB 47.4 million, pre-tax profit +RMB 0.7 million turning positive for the first time since listing, and operating cash flow +RMB 49.4 million turning positive for the first time in a half-year period. By segment, valve business revenue was RMB 207.3 million (+28.3%, TAVR implants 2,830 units/+36.5%, volume outpacing price), neuro-interventional RMB 217.2 million (+13.3%, driven by ischemic +45.4%, dragged by access products -15.4%); gross margin 68.3% (-1.8pp, attributed by the company to TAVR price adjustments + Trio early-stage mass-production costs + neuro-interventional VBP). The expense side was the main engine of profit improvement this period: selling expense ratio -13.5pp, R&D -23.5% (including a one-off plunge in external R&D service fees).
Reasons for deviation vs comparable periods: revenue growth (+20.1%) was higher than FY2025 full-year (+15.8%), driven by the Trio launch ramp (660+ cases in the half-year, 330 cases in July alone); profit improvement far exceeded revenue growth, reflecting the combination of operating leverage + expense compression, of which the sustainability of expense compression is the main question mark (see E1/E4 for details). Whether the market has priced this in: after the August interim results, the stock spiked on heavy volume and then fell back to the lower end of its 52-week range; sell-side target prices updated after the interims (Huatai HK$10.69, 2026-08-25) were not revised down with the share price — the positive news failed to sustainably lift the stock, and the market is awaiting formal verification of full-year breakeven and the VBP outcome. This report does not use sell-side target prices to infer the degree of market pricing.
Business model in brief: integrated "R&D/registration — manufacturing — academic promotion" of high-value interventional consumables. TAVR/TEER uses a direct-to-cardiology sales + academic training model (168-person sales team + medical affairs department, cumulatively covering 850+ hospitals and 410 independent operators); neuro-interventional uses a hybrid "direct sales + exclusive distribution" network (covering 3,000+ hospitals, exclusive distribution revenue FY2025 +110%). Revenue is one-off consumable sales, with no subscription/repurchase contracts; strong bargaining power over upstream suppliers (nitinol, pericardial materials, precision parts), weak over downstream — prices are set by provincial listing, volume-based procurement (VBP), and DRG; after TAVR listing prices were cut in multiple provinces from January 2026, the company's room to raise prices is essentially closed, and the growth model has switched to "volume × share."
Cash content of earnings: the cash conversion trajectory has kept improving through the loss-narrowing period — operating cash flow FY2023 -RMB 631 million (including BD milestone payments) → FY2024 -RMB 5.2 million → FY2025 -RMB 21 million → 2026H1 +RMB 49.4 million. The 2026H1 OCF turnaround was achieved despite a net working capital drag of about RMB 34 million (receivables +RMB 79.1 million, inventories +RMB 7.2 million, payables support +RMB 52.8 million) and was mainly driven by lower cash outlays for expenses — the turnaround itself is reasonably solid, but the "revenue→cash" chain is lengthening: trade receivables +481% in half a year, credit terms extended to 60–90 days, discounted notes with full recourse balance of RMB 129 million (only RMB 20 million at end-2024; derecognized but recourse risk remains). FCF on a TTM basis is still an outflow of about RMB 86 million (OCF +RMB 25.1 million - capex RMB 111 million); not yet self-funding.
Recurring earnings test: excluding the frontier technology segment, FY2024 -RMB 197 million → FY2025 -RMB 106 million → 2026H1 +RMB 24 million (our estimate) — the improvement slope is steep and the direction clear; but this basis does not cover group unallocated items (H1 net finance costs about RMB 8.2 million, FX + fair-value losses of RMB 25 million), so the actual "clean" recurring profit is thinner.
Return on capital and capex quality: during the loss period NOPAT is negative and ROIC is not applicable; the profitable unit for reference is the neuro-interventional segment (margin 23.0%–33.7%). Capex reached RMB 232 million in FY2025 (about 3.5x D&A), for the new Suzhou headquarters and the TaurusTrio-dedicated production line; 2026H1 fell to RMB 67.6 million (about 1.8x depreciation), with the construction peak passed — the company does not disclose a maintenance/growth split, so maintenance investment cannot be reliably estimated.
Red flags: ① Incremental cash mainly from borrowing — 2026H1 net new borrowings RMB 220 million vs operating cash flow +RMB 49.4 million; ② Top four customers account for 87.5% of revenue, largest customer 32.7%; ③ Frontier technology segment annualized loss of about RMB 66 million, with external financing carrying 6%/3% p.a. redemption clauses (debt-like), and consolidated losses still fully recognized.
Track record: partially delivered, pragmatic but execution pace on the slow side. ① Revenue guidance well delivered: Feb 2026 preview of FY2025 revenue RMB 700–720 million → actual RMB 712.9 million within range; Aug 2026 preview of H1 revenue RMB 415–435 million → actual RMB 424.5 million delivered again. ② FY2025 annual report's 2026 milestones: GeminiOne China approval delivered (2026-09); TaurusNXT still under review, EU MDR not yet approved — partially delivered. ③ IPO proceeds usage deadline extended twice from 2025 to 2028 — not delivered (delayed). No record of high-profile missed quantitative guidance; voluntary disclosure of semi-annual operational data + delivery of preview ranges indicates high disclosure transparency.
Shareholder-friendliness: neutral. Zero dividends since listing (common for loss-making 18A companies), no buybacks; the hedging signal is two rounds of open-market share purchases by founder/Chairman Dr. Zhang Yi (from Dec 2025 and from Mar 2026, each capped at HK$15 million, together about 1% of market cap) — modest in amount, more signal than substance. In January 2021 a placement of 5.3% of share capital netted HK$970 million; since 2026 only 2.225 million shares issued upon option exercises (dilution <0.5%), no abnormal share count dilution.
Risk signals: ① In March–June 2024, delayed publication of audited 2023 results and trading halt due to disagreement with the auditor over the initial valuation of financial assets worth HK$80 million — internal control track record issue; ② Management's interest-free loans of HK$12.035 million had repayment extended again from 2026–2027 to Dec 2026–Jan 2032; ③ Chairman and CEO roles held by one person, governance relies on independent non-executive directors as a check; ④ No disclosure of major shareholder sell-downs/pledges within the window.
Table: Segment structure (2026H1, RMB million)
| Segment | Revenue | Share | Gross margin | Revenue YoY | Segment profit | Business logic in one line |
|---|---|---|---|---|---|---|
| Transcatheter valves (TAVR/TEER) | 207.3 | 48.8% | 74.0% (FY2025: 78.7%) | +28.3% | -9.7 (loss narrowed 87.2%) | High price, high margin, driven by Trio ramp + share gains, approaching segment breakeven |
| Neuro-interventional | 217.2 | 51.2% | 62.9% (FY2025: 60.9%) | +13.3% | +73.2 (margin 33.7%) | The only profit engine; VBP trading price for volume, ischemic +45.4% |
| Frontier technologies | No revenue | — | — | — | -33.0 | IVL calcification remodeling/MonarQ TTVR/ReachTair three projects spun into independent subsidiaries, two have secured external financing |
Main profit segment: neuro-interventional — contributing all operating profit (+RMB 73.2 million) on 51.2% of revenue, subsidizing the valve segment's ramp-up losses (-RMB 9.7 million) and frontier technology investment (-RMB 33.3 million). Valve segment gross margin is about 11 percentage points higher than neuro-interventional (74.0% vs 62.9%), the gap coming from the technical barriers of TAVR systems with an ex-factory price of about RMB 73,000 per unit and unit-price structure, whereas neuro-interventional products have been squeezed by multiple rounds of VBP; but the valves' high gross margin is eaten up by heavy academic promotion expenses (TAVR selling expense ratio has long been above the group average), and the segment only approached breakeven in 2026H1. Neuro-interventional sub-lines are diverging: ischemic (thrombectomy/balloon) +45.4% is the growth spearhead, access -15.4% dragged by VBP price cuts and structural shift, hemorrhagic is the stable base.
Accounting red flags (by severity):
Cross-period consistency checks:
One correction to an upstream data sign: FY2024 excluding frontier technologies was still a loss of RMB 197 million (-RMB 228.5 million attributable loss + RMB 31.2 million frontier segment loss added back); some retellings mistakenly showed it as positive — the recurring profit turnaround occurred in 2026H1, not earlier.
Current market data (2026-10-09 closing freeze anchor): Share price HK$4.63, market cap HK$3.134 billion (677 million shares); PS(TTM) 3.41x, PS(2026E) 3.11x, EV/Sales(2026E) ~2.6x (net cash ~RMB478 million ≈ HK$560 million); PB ~1.45x (roughly 18th percentile over the past 1 year, 47th percentile over the past 3 years — during the earnings transition period, PB percentile is for reference only). PE(TTM) is negative and mechanically distorted, not used as a headline. Low liquidity note: average daily turnover of ~HK$2.3–3.3 million, ~0.01% of market cap; institutional entry/exit costs are high, so the valuation embeds a structural discount.
Table: Peer Benchmarking (snapshot as of 2026-10-09 close)
| Company | Market cap (HK$100M) | PS | Revenue growth (2025) | Profitability | Key differences vs. Peijia |
|---|---|---|---|---|---|
| Peijia Medical-B | 31.3 | PS(TTM) 3.4x | +15.8% (2026H1 +20.1%) | Pre-tax profit turned positive in 2026H1 | Dual platform: TAVR + neuro-intervention |
| Archimed Medical-B | 65.4 | 4.6x | +35.1% | Net profit RMB244 million | Pure neuro-intervention + peripheral; 2.5x the size, already profitable, overseas +115% |
| MicroPort NeuroScience | 46.6 | 5.0x | +3.8% | Net profit RMB184 million (-26.2%) | Pure neuro-intervention hemorrhagic leader, growth nearly stalled |
| Venus Medtech-B | 4.8 | 1.3x | -34.8% | Loss-making | TAVR distressed tail sample (revenue collapse → valuation collapse) |
| MicroPort CardioFlow-B | — | ~2.5x (distorted basis) | +12.3% | Loss-making | Basis not comparable after consolidating cardiac rhythm management |
*CardioFlow includes consolidated ICD business; basis distorted, shown for reference only.
Market-implied expectations: Back-solving from a mature-stage 25x PE anchor, the HK$3.134 billion market cap implies normalized net profit of ~RMB107 million — equivalent to "achieving ~13% net margin on the existing ~RMB820 million revenue base, with zero growth in perpetuity." Against reality: the company posted +20.1% revenue growth in 2026H1, recurring profitability has turned positive, and this report forecasts 2027E revenue of RMB940–1,020 million; peers Archimed and MicroPort NeuroScience have already achieved net margins of ~23%, so 13% is a conservative floor. In one sentence: at the current price, the market demands Peijia "achieve thin profitability and then stop," while the company's actual trajectory is a ramp-up amid a volume-price structural transition. But the reverse also holds — the same price can equally be read as the market pricing in a double tail of "failed turnaround + aggressive VBP (volume-based procurement)." These two interpretations cannot be distinguished from the price itself; only catalysts can adjudicate.
Three-layer value (EPV, HK$/share): Asset value ~3.19 (net book value at PB=1; intangibles of RMB733 million are ~42% of net assets — see risk chapter for impairment risk); EPV zero-growth 0.76–1.44 (neutral 1.44: based on 2026H1 recurring profit excluding frontier-technology and fair-value changes, annualized at ~RMB91.4 million, discounted at an 11% cost of equity — the midpoint of the 10–12% range for HK 18A medtech; the conservative 0.76 uses reported net profit); growth option residual = current price 4.63 - 1.44 ≈ HK$3.19, ~69% of the current price. The current price is mainly supported by the growth option — consistent with the pricing structure of a company in an earnings transition (EPV is a floor, not a final verdict) — but it means nearly 70% of the market cap is "prepaid growth"; if the ramp-up is falsified, the theoretical downside floor lies deep between EPV and asset value.
Three scenarios and odds (12–18 months):
| Scenario | Probability | Fair value range (HK$) | vs. current price | Key drivers |
|---|---|---|---|---|
| Bear | 0.28 | 2.6–3.0 | -44% to -35% | Second aggressive VBP price cut (proposed winning price <RMB130,000) + TEER volume stall + continued receivables bloat; 2027 revenue RMB760–800 million, pre-tax loss of RMB40–70 million again; valuation at PS 1.5–2.0x |
| Base | 0.52 | 5.0–6.5 | +8% to +40% | 2027E net profit RMB100–120 million × exit PE 25x (earnings-transition premium, anchored on peer steady-state 20–22x plus growth differential) ≈ HK$4.3–5.9; PS route (blended fair 3.3–3.8x × 2027E revenue) ≈ HK$5.4–6.7; blend of both routes |
| Bull | 0.20 | 8.0–9.5 | +73% to +105% | GeminiOne first-year volume exceeds expectations (>800 cases) + TaurusNXT approval moving up the price band + frontier-tech financing/deconsolidation replenishing cash; 2027E net profit ~RMB170 million × PE 28–30x |
At the current price of 4.63, it sits ~8% below the lower bound of the base-case range; the probability-weighted fair midpoint is ~HK$5.5, implying an expected return of ~+19%; downside to the bear-case midpoint is ~-40%, upside to the bull-case midpoint ~+89% — positively skewed odds but with a deep left tail, and the left-tail trigger (VBP tender opening) is outside the company's control. External anchors: on the pessimistic side, an industry-level evidence set (2025 total TAVR volume growth slowed to +8.1%, list price anchored at RMB150,000–160,000, and market discussion of a possible post-VBP drop to RMB100,000–120,000 — the latter is discussion-level, not an official document, and not used as a quantitative input), directionally consistent with this report's bear case, with no comparable single-stock target price; on the optimistic side, Huatai at HK$10.69 (2026-08-25) and CICC at HK$10.0 (2026-03-30) — both above this report's bull-case upper bound; this report's base case is 35–50% more conservative than theirs, on the grounds that sell-side coverage is thin (4 Buy / 0 Sell) and target prices were not revised down alongside the 37% share-price drawdown, limiting their reference value.
Conclusion: moderately undervalued. Assess quality and price separately. Quality — the earnings-inflection triple confirmation is a documented fact, two new products are ramping, and the dual-platform expense-amortization logic holds; but three shadows remain: receivables, expense compression, and frontier-tech drag. Price — PS trades at a 6–18% discount to blended fair value, PB at a low percentile, implied expectations are conservative; but the low-liquidity discount explains part of this, and there is market evidence of catalyst transmission failure. Target price HK$5.0–6.5 (base-case fair value), safety margin ~8% — a combination of thin margin and a deep left tail supports only cautious bullishness and staged entry, not a heavy bet.
In-house earnings forecast (results-reconciliation anchor):
| Period | Revenue (RMB 100M) | Net profit attributable (RMB 100M) | Key driver assumptions |
|---|---|---|---|
| 2026E | 8.4–8.8 | -0.4 to +0.3 (borderline) | H1 already realized RMB424.5 million; H2 Trio acceleration + first-quarter GeminiOne contribution; FX/fair-value changes are the biggest swing factor for the net profit sign |
| 2027E | 9.4–10.2 | 0.9–1.3 | GeminiOne full year RMB50–100 million + Trio ramp + neuro-intervention +12–18%; premise: mild VBP (proposed winning price ≥RMB150,000) |
Management has given no quantitative guidance; sell-side consensus earnings estimates are unavailable (CICC's 2026-03 forecast of 2026 net profit of ~RMB61 million is above this report's upper bound — formed before the interim report disclosed the "one-time R&D service fee savings"). At the next results disclosure, reconcile against this table: revenue deviation ≥10% to be attributed to volume/price/share; the net profit sign directly tests C1.
TAVR (transcatheter aortic valve replacement): China's 2025 procedure volume was ~18,636 cases (2023: 12,661 / +73%; 2024: 17,232 / +36.1%; 2025: +8.1% — growth slowing for three consecutive years), with trans-femoral access at 79.23% (Structural Heart Disease Annual Report Committee, "TAVR 2025 Annual Report," third-party clinical statistics). At an estimated ex-factory average price of ~RMB74,000 per case, the 2025 domestic ex-factory market size is ~RMB1.3–1.4 billion (this report's estimate: industry volume × Peijia's per-unit ex-factory price as an approximation). After the January 2026 adjustment, terminal list prices are anchored at ~RMB150,000–160,000 per set. Patient side: the base of elderly aortic stenosis patients is large; China's TAVR penetration is ~1% (19,000 annual implants vs. 20%+ penetration in Europe and the US) — the gap is the opportunity. What is happening on the demand side is not natural growth but a quantifiable "payment-accessibility" policy inflection: ① From January 2026, provincial list prices fell ~30% on average (manufacturer price-commitment filings under the NHSA's price risk management mechanism); ② Provincial insurance reimbursement expansion — Fujian added TAVR to its consumable reimbursement catalog in 2026-02 (15% co-pay), Liaoning began Category B reimbursement from 2026-04; ③ Per-patient out-of-pocket burden fell from the RMB100,000–200,000 level to ~RMB20,000 (based on RMB135,000 list price × 15% co-pay, a reduction of ~80%). Transmission chain: price cut (-30%) × collapse of co-pay threshold (-80%) → penetration climbing from ~1% toward double digits → procedure volume growth re-accelerating from 2025's +8.1%. Micro-level validation of this chain has already appeared: Peijia's 2026H1 implants +36.5% (~4x the industry's 2025 growth rate), Trio monthly implants reaching 330 in July — but whether "industry-wide volume elasticity > price collapse" will hold can only be confirmed with full-year 2026 industry data (expected January 2027); this is the industry's No. 1 validation point.
TEER (transcatheter edge-to-edge mitral valve repair): Early explosive-growth phase — implants of ~2,500 cases in 2024 → 4,334 in 2025 (+72.9%, per Jin-Di Medical press release citing annual report figures); the base of patients with mitral regurgitation requiring intervention is ~7.5 million (epidemiological estimate, reliability unverified), with current penetration below 0.1%. Rough market size estimate at ex-factory prices: RMB400–600 million (estimated; no official figure obtained). Following Abbott's mature path of ~55,000 annual implants globally, 40–70% high growth can be expected over the next 2–3 years.
Neuro-intervention: The 2025 China market is ~RMB12.8 billion (hemorrhagic RMB3.2bn / ischemic RMB4.4bn / access RMB5.2bn, per Guosen Securities forecasts), projected to reach RMB31 billion by 2030 (~19% CAGR; VBP price cuts may push the value-basis figure below this forecast). Thrombectomy penetration: China ~1.7% vs. US ~11.8% (2019 basis) — the ischemic segment is the steepest penetration sub-line (Peijia's 2026H1 ischemic +45.4% aligns with this).
Upstream (nickel-titanium alloys, platinum-iridium radiopaque materials, bovine/porcine pericardial valve leaflets, precision balloon catheter components): supply is ample with low single-supplier dependence; device makers have strong bargaining power upstream and materials costs are a low share of sales price. Midstream (R&D/registration + manufacturing) is where value accumulates: Peijia's TAVR segment gross margin was 78.7% (FY2025), neuro-intervention 60.9% — but TAVR's academic promotion (physician education / proctoring / patient screening) consumes substantial gross margin, and its selling expense ratio is persistently higher than neuro-intervention's. Downstream is tertiary-hospital specialty teams + insurance payment: the two-invoice system and VBP have squeezed distribution margins to the bone; bargaining power against payers is weak — list prices / VBP / DRG determine prices, and manufacturers trade "price-commitment filings" for hospital listing and reimbursement eligibility; bargaining power against hospitals is moderate (operator stickiness and proctoring systems create switching costs: Peijia has 410 independent operators and 330 proctoring experts; a mature center takes years to cultivate). Value distribution trend: residual value concentrates in "manufacturing gross margin + operator service networks"; pure distribution models are being cleared out.
TAVR: supply is significantly more crowded than demand. Six players approved (Venus Medtech, CardioFlow, Peijia, Jiecheng + Medtronic, Edwards); in 2024–2025, 5+ new registrations from Baiwen (Baili), Jiashi (Kester), Niumai, Lepu, Jinshi and others landed intensively, with 10+ registrations in the pipeline — supply-side crowding is the core reason for this round of price cuts. Competition has effectively become price-based: the list-price band has compressed to RMB131,000 (CardioFlow legacy certificate, lowest nationwide) – RMB199,000 (Medtronic new certificate); Peijia's TaurusElite at RMB135,000 is positioned at the low-price domestic end, TaurusMax at RMB159,000 in mid-to-high end. Landscape evolution: Venus Medtech once dominated with >50% share in 2022; with 2025 revenue -34.8% (2026H1 a further -27.6%), its share has fallen sharply; Peijia's share rose steadily from 4.7% in 2021 to ~21% in 2025 (society total-volume basis) / 26.4% (trans-femoral denominator, company estimate); CardioFlow +12.3% holds steady — "Peijia leading domestic players, CardioFlow following, Venus clearing out" accurately describes the current landscape, but precise CR3 values are unavailable (not all players disclose implant volumes). Entry barriers: NMPA Class III registration takes 5–8 years plus multi-center clinicals, operator proctoring systems, hospital access / insurance coding; amid the capital-market chill, new entrants struggle to raise funds — the barriers remain, but they cannot stop price wars among those already holding registrations.
TEER: land-grab in the introduction phase; competition mild. In 2025, Jin-Di's DragonFly topped the market with 2,043 cases (~47%, press-release basis); Abbott's MitraClip first-mover share from 2020 was overtaken; Hankyu's ValveClamp and subsequent approvals divide the rest; Peijia's GeminiOne (2026-09) is the 4th–5th domestic product, with no share yet.
Neuro-intervention: VBP clearing + domestic substitution in parallel. Before coil VBP, imports (Medtronic, Stryker, etc.) dominated absolutely; after VBP, domestic share rose to ~26% (2024, secondhand citation, unverified); Peijia's thrombectomy stent holds ~17% market share (No. 2 overall / No. 1 domestic), balloon category >25% (No. 1 overall, company basis 2025) — niche single-product champion + VBP wins delivering "volume for price" (Fastunnel volume +300%). Competitive intensity: 20+ domestic players with homogeneous products — "rat race before scale" — but VBP rules are becoming more rational (low-price winners subject to key supervision), favoring leaders with product strength + cost advantages.
The industry is in a stage of "mid-growth meeting price restructuring": the volume penetration logic (low base + payment expansion) is unchanged, while price controls (list price -30%, VBP in progress) rigidly suppress revenue elasticity — "volume for price" is the theme for the next 2–3 years. Regulation is pushing in both directions: the squeeze side — the Gansu-led inter-provincial heart valve VBP alliance launched on 2025-10-31 (reportedly covering 20+ provinces; as of this report's date, no tender opening or procurement documents — the industry's biggest overhang); coil re-tenders and multi-province neuro-intervention alliances becoming routine. The support side — NMPA innovative-device green channel (Peijia's shockwave calcification remodeling and ReachTact both included) + the September 2025 drug regulator's ten measures supporting high-end device innovation; DRG/DIP exclusion-payment mechanisms for innovative devices gradually clarified; provincial insurance reimbursement expansion (Fujian/Liaoning). Leading indicators: monthly/quarterly implant volumes, pace of provincial reimbursement expansion, VBP volume reporting and tender openings, registration approval cadence, hospital coverage (Peijia TAVR 850+ / neuro-intervention 3,000+).
A dual-platform company: domestic TAVR frontrunner + neuro-intervention niche champion. TAVR: share from 4.7% in 2021 → ~21–26.4% in 2025 (dual basis); implant growth consistently 2x+ the industry; TaurusTrio establishes a domestically exclusive dual-indication position covering "aortic stenosis + aortic regurgitation" (parent product JenaValve Trilogy received FDA PMA approval in March 2026, independently validating the AR-TAVR赛道); relative weaknesses: overseas revenue share near zero (DCwire's FDA 510(k) in 2026-03 is just a start), a single plant fighting 10+ registrations of crowded supply. Neuro-intervention: revenue is ~54% of MicroPort NeuroScience's and ~62% of Archimed's neuro line, but growth (+13.3%) is above MicroPort NeuroScience (+3.8%) and below Archimed (+31.1%), relying on niche single-product share (No. 1 in balloons / No. 1 domestic in thrombectomy) + exclusive distribution to amplify revenue. Share-basis disclaimer: TAVR share is on a company basis (implants ÷ industry association annual report denominator); no independent third-party share data exists; the two denominator bases are listed side by side above — must be noted when cited. Moat sources: breadth of the registration portfolio (4 TAVR + 1 TEER + 15 in-house neuro-intervention + 4 exclusively distributed) + operator proctoring network + dual-platform "cardio-cerebrovascular" expense amortization (group selling expense ratio 45.0% → 27.6%).
The valuation and revenue realization of high-value interventional consumables are determined by three chains, whose time structure general financial frameworks tend to miss:
① Registration matrix and approval cadence. Peijia currently holds 4 TAVR products (TaurusOne/Elite/Max/Trio) + TEER GeminiOne (2026-09) + 15 in-house and 4 exclusively distributed neuro-intervention products; key registrations in the pipeline: TaurusNXT (accepted 2025-12; following GeminiOne's ~11-month "acceptance → approval" pace, window 2026Q4–2027Q1), GeminiOne EU MDR (submitted 2026-02), HighLife TSMVR China registration clinical (CE already obtained). The registration portfolio's "breadth × generation" determines price-band positioning — Trio's exclusive AR indication and NXT's push into high-end dry valves are the company's two cards for maintaining ASP in a VBP price-cut environment.
② The ramp curve of implants–hospital coverage–operator cultivation. Consumable volume growth is not distribution but "operator education": only ~700–800 hospitals nationwide can perform TAVR; Peijia covers 850+ (with ~70 added in 2026H1) and has 410 independent operators; GeminiOne's ramp slope depends on hospital listing numbers and training-camp cadence (benchmark: Trio achieved 660 implants within 6 months of launch). Operating data (implants/hospital count) precede financial-statement revenue recognition, and the company has a practice of voluntarily disclosing semi-annual operating data — the first-hand high-frequency signal for tracking the ramp.
③ The volume-price game of VBP and list pricing. Multiple rounds of neuro-intervention VBP have proven the "win → share jump → volume for price" playbook viable (Fastunnel +300%, neuro-intervention segment margin rebounding to 33.7%); TAVR is on the eve of its first nationwide joint procurement (Gansu alliance); the coil experience (first round -46.8%, re-tender around -10%) suggests the deepest cuts come in the first round, converging thereafter. The dual implications for Peijia: a mild tender = volume up with gradual price declines (volume growth in lower-tier hospitals); an aggressive tender = a further 15–30% ASP cut (breaching RMB131,000 would trigger the bear case) — this is the single largest pricing event of the next 6–12 months, and it is outside the company's control.
Rating: Cautiously Bullish | Confidence 0.55 | Time Horizon 12–18 months. Basis for judgment: the triple confirmation of the earnings inflection point is a document-level fact, the trends in market share and new product ramp-up are clear, and the current price implies conservative expectations—direction is bullish; however, the margin of safety is only about 8%, the left tail (aggressive VBP procurement + failure to turn profitable) is as deep as -40% and beyond the company's control, and low liquidity means there is no timetable for expectation-gap closure—hence confidence is moderately low. Strategy: accumulate in tranches within the HK$4.0–4.7 range, target HK$5.0–6.5 (reassess upon breaking above 5.0 into fair-value territory; evaluate exit upon breaking above 6.5), and mandatorily re-examine the thesis if the price falls below HK$3.70 (near the 52-week low). Liquidity risk warning: average daily turnover of approximately HK$2.3–3.3 million, about 0.01% of market capitalization, well below the 0.1% benchmark—any directional resolution will materialize in the form of price gaps; position size must be matched to exitability.
Risks and Catalysts (next 12 months, in chronological order):
Reconciliation commitment: at the next results disclosure (expected late March 2027), this report's 2026E/2027E earnings forecasts will be reconciled item by item—revenue variances ≥10% will be attributed to volume/price/market share, and the sign of net profit will directly test whether the C1 statement of "narrow-margin turnaround to profitability" is realized.
Report date: 2026-10-10. Price anchor: 2026-10-09 closing price of HK$4.63. This report was generated by Loyan AI; all financial data can be traced back to the cited original announcements; estimation items have their bases and formulas noted. This report does not constitute investment advice.